The present invention relates to a method of treating MS in a human patient in need of such treatment and comprises administering to said patient a combination therapy in a single oral dosage form (e.g. a tablet or capsule) of dim ethyifurrta rate and one agent selected from teriflunomide (or its prodrug leflunomide) fingolimod and laquinimod. This combination is more effective than the single agents alone and/or has reduced side effects and better tolerability than the single agents alone and/o...

The present invention relates to a method of treating MS in a human patient in need of such treatment and comprises administering to said patient a combination therapy in a single oral dosage form (e.g. a tablet or capsule) of dimethylfumarate and teriflunomide (or its prodrug leflunomide) which is more effective than the single agents alone and/or has reduced side effects and better tolerability than the single agents alone and/or can be given in a reduced frequency. Moreover the present invent...

The present invention relates to a method of treating MS in a human patient in need of such treatment and comprises administering to said patient a combination therapy in a single oral dosage form (e.g. a tablet or capsule) of dimethylfumarate and one agent selected from teriflunomide (or its prodrug leflunomide) fingolimod and laquinimod. This combination is more effective than the single agents alone and/or has reduced side effects and better tolerability than the single agents alone and/or ca...

The invention relates to methods of selecting a subject and methods of treating the subject with an anti-VLA-1 antibody. In one embodiment the first therapeutic agent is a DMARD (Disease Modifying Antirheumatic Drug) such as gold salts; hydroxychloroquine; an antifolate such as methotrexate; a pyrimidine synthesis inhibitor such as leflunomide; or a sulfa drug such as sulfasalazine. For example the DMARD can be methotrexate administered at a dose of mg/week or less; leflunomide administered at a...

The invention relates to the use of polycycloolefins in electronic devices and more specifically to the use of such polycycloolefins as interlayers applied to insulating layers used in electronic devices the electronic devices that encompass such polycycloolefin interlayers and processes for preparing such polycycloolefin interlayers and electronic devices.

The invention relates to the use of polycycloolefins in electronic devices and more specifically to the use of such polycycloolefins as interlayers applied to insulating layers used in electronic devices, the electronic devices that encompass such polycycloolefin interlayers and processes for preparing such polycycloolefin interlayers and electronic devices.

The invention relates to methods of selecting a subject and methods of treating the subject with an anti-VLA-l antibody. In one embodiment the first therapeutic agent is a DMARD (Disease Modifying Antirheumatic Drug) such as gold salts; hydroxychloroquine; an antifolate such as methotrexate; a pynmidine synthesis inhibitor such as leflunomide; or a sulfa drug such as sulfasalazine. For example the DMARD can be methotrexate administered at a dose of mg/week or less; leflunomide administered at a ...

In the present invention there are described soluble CTLA4 fusion molecules containing extracellular domain of the CTLA4 molecule and their use optionally in combination with a second agent being selected from the group consisting of corticosteroids nonsteroidal anti-inflammatory agents cyclosporine prednisone azathioprine methotrexate TNF-alpha blockers or antagonists hydroxychloroquine sulphasalazine gold salts anakinra cyclophosphamide and leflunomide and their use as well as pharmaceutical c...